Highlights

  • Third quarter net loss was USD 7,979 thousand against USD 10,083 thousand.
  • Cash and cash equivalents were USD 30,900 thousand at September 30, 2026.
  • Net cash from financing for nine months was USD 42,322 thousand.
  • Complete Phase 2 AMPLIFY-7P results were presented at ESMO in October 2026.

Elicio Therapeutics, Inc. (NASDAQ:ELTX) shares were trading near their all-time low at USD 1.40 on November 6, 2026, down 0.36% on the day. The clinical-stage company reported a third quarter net loss of USD 7,979 thousand, or USD 0.30 per share.

Elicio is a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers. Its pipeline targets driver tumor mutations using common, well-characterized neoantigens.

Recent Development

In October 2026, the company presented complete Phase 2 AMPLIFY-7P trial results in a late-breaking oral session at the ESMO Congress 2026. The filing says the results were also published in Nature Medicine.

Third Quarter Results

Total operating expenses were USD 8,452 thousand against USD 8,045 thousand, and the loss from operations matched those figures. The net loss was USD 7,979 thousand against USD 10,083 thousand, and the loss per share was USD 0.30 against USD 0.60.

Research and development expenses were USD 4.9 million against USD 5.0 million, a decrease of USD 0.1 million that the filing links to lower clinical trial costs. The company recognized a net gain of USD 0.7 million in the quarter and USD 2.2 million for the nine months on remeasurement of liability-classified July 2024 common warrants.

Nine-Month Results

Operating expenses were USD 29,483 thousand against USD 28,872 thousand. The net loss was USD 28,019 thousand, or USD 1.32 per share, against USD 31,853 thousand, or USD 2.09 per share.

Cash and Balance Sheet

Cash and cash equivalents were USD 30,900 thousand against USD 18,563 thousand at December 31, 2025. Net cash used in Operating Activities was USD 30,174 thousand against USD 30,155 thousand, and net cash provided by financing activities was USD 42,322 thousand against USD 31,832 thousand.

Total Assets were USD 39,596 thousand against USD 25,862 thousand. Total liabilities were USD 20,745 thousand against USD 24,226 thousand, and total stockholders' Equity was USD 18,851 thousand against USD 1,636 thousand. The accumulated Deficit was USD 261,691 thousand.

Going Concern Language

The filing states that the company's losses from operations, negative operating cash flows and accumulated deficit, along with the additional Capital needed to fund operations for at least twelve months from issuance, raise substantial doubt about its ability to continue as a going concern. There were 28,307,225 shares outstanding as of November 3, 2026.